Market Research Reports

Preimplantation Genetic Diagnosis (PGD) Market - Global Industry Analysis, Market Size, Market Share And Forecast 2012 - 2018

86pages
Published Date: 2012-10-29
 

Description




Description

This report covers aspects of the global Preimplantation Genetic Diagnosis (PGD) market. It covers the performance of the various types and applications of PGD in terms of their revenue as well as the performance of respective segments from the regional perspective. The global market for PGD is classified into four zones namely, North America, Europe, Asia Pacific and rest of the world (ROW). Moreover, the report also provides in-depth analysis of the segments of the preimplantation genetic diagnosis market in terms of its product types and applications, with their estimated and forecasted market size from 2011 to 2018, along with their compounded annual growth rate.

The various applications covered in the market are PGD for identification of HLA compatible embryos, identification of late-onset diseases, genetically inherited diseases and improving prognosis for IVF patients. The analysis covers the estimates and forecast of these segments for the period 2011 to 2018. The report also covers the analysis of the drivers, restraints and opportunities concerning the PGD market. The analysis of the overall competitiveness of the PGD market is also conducted and covered in the report. These factors along with the strategic recommendations would be highly helpful in taking strategic corporate decisions related to the PGD market. 

In addition, this report covers the prime players currently active in the PGD market. The company profiling done in this report will be of vital assistance in mapping the competition in the market. The profiles cover the financial and strategic overview of the key players and their SWOT analysis and recent developments.

Secondary research has been employed for deriving the market numbers for each segment of the research report and further findings have been validated with C-level executives of major companies operating in the preimplantation genetic diagnosis market. This research is specially designed to estimate and analyze the performance of preimplantation genetic diagnosis in a global scenario. The report presents a detailed assessment of the market players’ strategies, and winning factors for them by segmenting the global preimplantation genetic diagnosis market as:

Preimplantation genetic diagnosis market by product types
  • For determination of chromosomal abnormalities
  • Aneuploidy
  • HLA typing
  • Gender selection
  • X-linked diseases
  • Single gene disorders
  • Other genetic disorders
Preimplantation genetic diagnosis market by application
  • Determination of HLA compatible embryos for stem cell therapy
  • Late-onset genetic disorders
  • Improving prognosis for in vitro fertilization patients
  • Inherited genetic diseases
  • Others
In addition a detailed cross sectional analysis of the above segments with respect to the below mentioned geographical markets has been performed:
  • North America
  • Europe 
  • Asia
  • Rest of the World (RoW)

Table of Contents




TABLE OF CONTENTS

CHAPTER 1 PREFACE
1.1 RESEARCH SCOPE AND DESCRIPTION
1.2 RESEARCH METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY AND MARKET OVERVIEW

CHAPTER 3 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS MARKET ANALYSIS
3.1 BACKGROUND
3.2 MARKET TRENDS AND FUTURE OUTLOOK
3.3 MARKET SHARE
3.4 GROWTH DRIVERS
      3.4.1 INCREASED SCOPE OF DIRECT-TO-CONSUMER GENETIC TESTING METHODS
      3.4.2 INCREASING INCIDENCES OF GENETIC DISEASES
      3.4.3 RISING RATE OF INFERTILITY
      3.4.4 ASSISTANCE IN HEALTHY AND SUCCESSFUL FOETAL IMPLANTATION
3.5 RESTRAINTS
      3.5.1 NON AVAILABILITY OF EMBRYOS FOR TRANSFER
      3.5.2 SCIENTIFIC, ETHICAL AND POLICY ISSUES
3.6 OPPORTUNITIES
      3.6.1 INNOVATION IN CANCER PREVENTION
      3.6.2 INNOVATION IN THE FIELD OF GENETICS
3.7 INDUSTRY CHALLENGES AND STRATEGIC RECOMMENDATIONS
3.8 PORTER’S FIVE FORCES ANALYSIS
      3.8.1 SUPPLIERS’ POWER
      3.8.2 BUYERS’ POWER
      3.8.3 THREAT OF NEW ENTRANTS
      3.8.4 THREAT FROM SUBSTITUTES
      3.8.5 INTERNAL RIVALRY
3.9 MARKET ATTRACTIVENESS ANALYSIS

CHAPTER 4 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS MARKET ANALYSIS
4.1 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND FORECAST, 2011 - 2018
4.2 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET VOLUME AND FORECAST, 2011 - 2018
4.3 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS CYCLES PERFORMED, BY GEOGRAPHY, 2011 - 2018

CHAPTER 5 PREIMPLANTATION GENETIC DIAGNOSIS MARKET BY TYPE
5.1 PGD FOR DETERMINATION OF CHOROMOSOMAL ABNORMALITIES
      5.1.1 MARKET SIZE AND FORECAST
5.2 PGD FOR ANEUPLOIDY
      5.2.1 MARKET SIZE AND FORECAST
5.3 PGD FOR HLA TYPING
      5.3.1 MARKET SIZE AND FORECAST
5.4 PGD FOR GENDER SELECTION
      5.4.1 MARKET SIZE AND FORECAST
5.5 PGD FOR X-LINKED DISEASES
      5.5.1 MARKET SIZE AND FORECAST
5.6 PGD FOR SINGLE GENE DISORDERS
      5.6.1 MARKET SIZE AND FORECAST
5.7 OTHER GENETIC DISORDERS
      5.7.1 MARKET SIZE AND FORECAST

CHAPTER 6 PREIMPLANTATION GENETIC DIAGNOSIS BY APPLICATIONS
6.1 IDENTIFICATION OF HLA-COMPATIBLE EMBRYOS FOR STEM CELL THERAPY
      6.1.1 MARKET TREND ANALYSIS
6.2 LATE-ONSET GENETIC DISORDERS
      6.2.1 MARKET TREND ANALYSIS
6.3 IMPROVING PROGNOSIS FOR IN VITRO FERTILIZATION PATIENTS
6.4 INHERITED GENETIC DISEASE
      6.4.1 MARKET TREND ANALYSIS
6.5 OTHERS
      6.5.1 MARKET TREND ANALYSIS

CHAPTER 7 PREIMPLANTATION GENETIC DIAGNOSIS MARKET BY GEOGRAPHY
7.1 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS MARKET
      7.1.1 GLOBAL MARKET TREND AND FORECAST
7.2 NORTH AMERICA
      7.2.1 MARKET SIZE AND FORECAST
      7.2.2 HIGHLIGHTS OF LEGAL PROVISIONS IN MAJOR NORTH AMERICAN NATIONS
              7.2.2.1 United States of America
              7.2.2.2 Canada
7.3 EUROPE
      7.3.1 MARKET SIZE AND FORECAST
      7.3.2 HIGHLIGHTS OF LEGAL PROVISIONS IN MAJOR EUROPEAN NATIONS
              7.3.2.1 United Kingdom
              7.3.2.2 France
              7.3.2.3 Germany
              7.3.2.4 The Netherlands
              7.3.2.5 Switzerland
7.4 ASIA
     7.4.1 MARKET SIZE AND FORECAST
     7.4.2 HIGHLIGHTS OF LEGAL PROVISIONS IN ASIA 
              7.4.2.1 China
              7.4.2.2 India
              7.4.2.3 Japan
              7.4.2.4 Singapore
7.5 REST OF WORLD
      7.5.1 MARKET SIZE AND FORECAST
              7.5.1.1 South Africa
              7.5.1.2 Israel

CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 OVERVIEW 
8.2 MARKET SHARE BY KEY PLAYERS 

CHAPTER 9 RECOMMENDATIONS
9.1 MARKET STRATEGY FOR SUCCESS
      9.1.1 INCREASE THE AWARENESS ABOUT PGD
      9.1.2 INCREASE THE NUMBER OF IVF AND PGD CENTERS
      9.1.3 EFFICIENT PATIENT COUNSELING
      9.1.4 INCREASE THE AFFORDABILITY OF PGD AND IVF
9.2 BARRIERS TO BE CONSIDERED
9.3 FUTURE ASSUMPTIONS

CHAPTER 10 COMPANY PROFILES
10.1 AMGEN
      10.1.1 COMPANY OVERVIEW
      10.1.2 FINANCIAL OVERVIEW
      10.1.3 SWOT ANALYSIS
      10.1.4 RECENT DEVELOPMENTS
10.2 QUEST DIAGNOSTICS
      10.2.1 COMPANY OVERVIEW
      10.2.2 FINANCIAL OVERVIEW
      10.2.3 SWOT ANALYSIS
      10.2.4 STRATEGIC OVERVIEW
      10.2.5 RECENT DEVELOPMENTS
10.3 GENENTECH INC. 
      10.3.1 COMPANY OVERVIEW
      10.3.2 SWOT ANALYSIS
      10.3.3 RECENT DEVELOPMENTS
10.4 VERTEX
      10.4.1 COMPANY OVERVIEW
      10.4.2 FINANCIAL OVERVIEW
      10.4.3 SWOT ANALYSIS
10.4.4 RECENT DEVELOPMENT
10.5 GENESIS GENETICS
      10.5.1 COMPANY OVERVIEW
      10.5.2 FINANCIAL OVERVIEW
      10.5.3 RECENT DEVELOPMENTS
10.6 REPROGENETICS
      10.6.1 COMPANY OVERVIEW
      10.6.2 PRODUCT OVERVIEW
10.7 LABORATORY CORPORATION OF AMERICA HOLDINGS (LABCORP) 
      10.7.1 COMPANY OVERVIEW
      10.7.2 FINANCIAL OVERVIEW
      10.7.3 SWOT ANALYSIS
      10.7.4 RECENT DEVELOPMENTS
10.8 REPRODUCTIVE GENETICS INSTITUTE
      10.8.1 COMPANY OVERVIEW
      10.8.2 RECENT DEVELOPMENTS
10.9 F. HOFFMANN-LA ROCHE
      10.9.1 COMPANY OVERVIEW
      10.9.2 FINANCIAL OVERVIEW
      10.9.3 SWOT ANALYSIS
      10.9.4 STRATEGIC OVERVIEW
10.10 ATHENA DIAGNOSTICS
      10.10.1 COMPANY OVERVIEW
      10.10.2 FINANCIAL OVERVIEW
      10.10.3 STRATEGIC OVERVIEW
10.11 GENZYME CORP
      10.11.1 COMPANY OVERVIEW
      10.11.2 FINANCIAL OVERVIEW
      10.11.3 SWOT ANALYSIS
      10.11.4 RECENT DEVELOPMENTS

LIST OF FIGURES

FIG. 1 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE, 2011 – 2018
FIG. 2 PREIMPLANTATION GENETIC DIAGNOSIS PROCESS
FIG. 3 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET ATTRACTIVENESS ANALYSIS, 2011
FIG. 4 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET ATTRACTIVENESS ANALYSIS, 2018
FIG. 5 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE, 2011 – 2018, USD MILLION
FIG. 6 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET, 2011 – 2018, VOLUME (NUMBER OF CYCLES PERFORMED) 
FIG. 7 PGD FOR DETERMINATION OF CHROMOSOMAL ABNORMALITIES, GLOBAL MARKET SIZE, 2011 – 2018, USD MILLION
FIG. 8 PGD FOR DETERMINATION OF ANEUPLOIDY, GLOBAL MARKET SIZE, 2011 – 2018, USD MILLION
FIG. 9 PGD FOR DETERMINATION OF HLA TYPING, GLOBAL MARKET SIZE, 2011 – 2018, USD MILLION
FIG. 10 PGD FOR GENDER SELECTION, GLOBAL MARKET SIZE, 2011 – 2018, USD MILLION
FIG. 11 PGD FOR X-LINKED DISEASES, GLOBAL MARKET SIZE, 2011 – 2018, USD MILLION
FIG. 12 PGD FOR DETERMINATION OF SINGLE GENE DISORDERS, GLOBAL MARKET SIZE, 2011 – 2018, USD MILLION
FIG. 13 PGD FOR DETERMINATION OF OTHER GENETIC DISORDERS, GLOBAL MARKET SIZE, 2011 – 2018, USD MILLION
FIG. 14 PGD IDENTIFICATION OF HLA COMPATIBLE EMBRYOS FOR STEM CELL THERAPY, GLOBAL MARKET SIZE, 2011 – 2018, USD MILLION
FIG. 15 PGD FOR DETERMINATION OF OTHER GENETIC DISORDERS, GLOBAL MARKET SIZE, 2011 – 2018, USD MILLION
FIG. 16 PGD FOR DETERMINATION OF INHERITED GENETIC DISEASES, GLOBAL MARKET SIZE, 2011 – 2018, USD MILLION
FIG. 17 PGD FOR DETERMINATION OF OTHER GENETIC DISORDERS, GLOBAL MARKET SIZE, 2011 – 2018, USD MILLION
FIG. 18 GLOBAL PGD MARKET FORECAST, BY GEOGRAPHY, 2011 AND 2018, PRECENTAGE
FIG. 19 LABCORP, NET INCOME, 2008 - 2010
FIG. 20 GENZYME CORP, NET INCOME, 2008 - 2010

LIST OF TABLES

TABLE 1 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS CYCLES, BY GEOGRAPHY
TABLE 2 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS MARKET SIZE, BY GEOGRAPHY, 2011 – 2018, USD MILLION
TABLE 3 NORTH AMERICA PGD MARKET, SIZE AND FORECAST, 2011 – 2018, USD MILLION
TABLE 4 NORTH AMERICA PGD MARKET, BY VOLUME AND REVENUE, 2011 – 2018
TABLE 5 EUROPE PGD MARKET, SIZE AND FORECAST, 2011 – 2018, USD MILLION
TABLE 6 EUROPE PGD MARKET, BY VOLUME AND REVENUE, 2011 – 2018
TABLE 7 ASIA PGD MARKET, SIZE AND FORECAST, 2011 – 2018, USD MILLION
TABLE 8 ASIA PGD MARKET, BY VOLUME AND REVENUE, 2011 – 2018
TABLE 9 REST OF WORLD PGD MARKET, SIZE AND FORECAST, 2011 – 2018, USD MILLION
TABLE 10 REST OF THE WORLD PGD MARKET, BY VOLUME AND REVENUE, 2011 – 2018
TABLE 11 MARKET POSITIONING OF MAJOR PREIMPLANTATION GENETIC DIAGNOSIS  MARKET PLAYERS, BY GEOGRAPHY

Market Overview




Increasing incidences of genetic diseases and rising rate of infertility are giving rise to diagnostic procedures like preimplantation genetic diagnosis. Preimplantation genetic diagnosis market is at its early stage and hence opening up new opportunities for expansion of this industry with continuous developments and emergence of new players. This virtually untapped market harbors numerous targets for strategic achievement and provides new applications for advanced genomic technologies. 

Increasing number of services in preimplantation genetic diagnosis (PGD) industry will attract more number of patients, thus boosting the industry growth. Market characteristics of PGD industry are dictated by dynamics of infertility markets. The greater market saturation achieved by expanding PGD services will promote the overall growth of this market in the future. 

Effectiveness of PGD in detecting chromosomal and single gene disorders and its high reliability of results are major factors driving the growth of this industry. Success of ongoing clinical trials, further research in the field, and support from big players in the field are some important factors that are expected to drive the growth in future. 

Market Segmentation

Genetic Testing of Embryo for Screening Purpose
  • Chromosomal testing for Translocations
  • Aneuploidy
  • Gender determination
Genetic Testing of Embryo for Diagnostic Purpose
  • Single Gene Mutation Detection
  • Human Leukocyte Antigen Compatibility Testing  
The research report for preimplantation genetic diagnosis market analyzes this market depending on its market segments and major geographies. Geographies analyzed under this research report are 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World 
This report includes a comprehensive analysis of current trends in the market, industry growth drivers, factors affecting market growth, market structure, and industry projections for the upcoming years. This report also includes detailed analysis of technological improvements in the field, Porter’s five force model analysis, and complete company profiles of top industry players. 

Report provides review of micro and macro factors significant with respect to new entrants and existing market players with value chain analysis. 

Major Players 

Some of the major players dominating this market are Reprogenetics, LabCorp, Genesis Genetics Institute, Reproductive Genetics Institute, Amgen, Athena Diagnostics Inc., Chiron Inc, Genentech Inc., Genzyme Corp., Millenium Pharmaceuticals, Myriad Genetics, Orchid Biosciences, Pfizer Inc., Quest Diagnostics, Roche, Sanofi-Aventis, Vertex Pharmaceuticals Inc, Wyeth-Ayerst Inc., and others. 

Enquiry Before Buying




Free Market Analysis




Innovation in the field of genetics and awareness about the prevention of genetically inherited diseases plays an important role in the development of the preimplantation genetic diagnosis (PGD) market. Accessibility to PGD through developments in the field of direct to consumer diagnosis methods, increase in the number of cases of genetically inherited diseases, increase in the average maternal age etc are some of the factors which are at present responsible for the growth of the demand for PGD worldwide. 

PGD is adjunct to the in vitro fertilization (IVF) process. Thus the progress of PGD will always correspond to that of IVF. PGD is highly instrumental in improving prognosis of IVF. Since only the chromosomally fit embryo is implanted and further pregnancy is conceived, the chances of miscarriage or abortion owing to aneuploidy or other chromosomal abnormalities significantly decreases. 

The lack of viable alternatives to PGD also makes the future of the PGD market very lucrative. However, certain ethical and societal barriers may hamper the growth of the PGD market to some extent. On the other hand, the high entry barriers and use of high end technology in PGD makes the competitive rivalry in the PGD market very intense. 

At present the market for PGD, performed for HLA typing enjoys the highest growth. Awareness about avoiding genetically inherited diseases especially the late-onset diseases and genetically inherited cancer will drive the future of the PGD market. Gender selection for family balancing is at present prohibited in majority of the countries worldwide. Regulatory reforms in this field may also help in the growth of the PGD market. Few regulatory reforms, change in the moral perspective of the public, technical innovation and change in the pricing policy will make the PGD market more attractive and thus growth will increase.
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research